Morepen Laboratories Ltd (MOREPENLAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 546345,
    "name": "Morepen Labs.",
    "stock_name": "Morepen Labs.",
    "full_name": "Morepen Laboratories Ltd",
    "name_url": "stocks-analysis/morepen-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "37.52",
    "chg": 1.61,
    "chgp": "4.48%",
    "dir": 1,
    "prev_price": "35.91",
    "mcapval": "2,042.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 500288,
    "symbol": "MOREPENLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE083A01026",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "26.36 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/morepen-labs-546345-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Morepen Laboratories Faces Challenging Market Conditions Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/morepen-laboratories-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3727841",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MorepenLaborato_mojoScore_3727841.png",
        "date": "2025-11-25 08:42:08",
        "description": "Morepen Laboratories, a player in the Pharmaceuticals & Biotechnology sector, is currently navigating a complex market environment marked by subdued financial results and cautious technical indicators. Recent shifts in evaluation metrics reflect a nuanced perspective on the company’s quality, valuation, financial trends, and technical outlook, underscoring the challenges it faces amid broader market dynamics."
      },
      {
        "title": "Why is Morepen Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-morepen-labs-fallingrising-3726924",
        "imagepath": "",
        "date": "2025-11-25 01:15:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>On 24 November, Morepen Laboratories closed at ₹43.10, down by ₹0.91 or 2.07% from the previous session. This drop continues a downward trend, with the stock having fallen for eight consecutive days, resulting in an 8.57% loss over this period. The stock is trading close to its 52-week low, just 3.34% above the lowest price of ₹41.66 recorded during the past year. This proximity to the annual low signals persistent selling pressure and a lack of positive catalysts to reverse the trend.</p>\n<p>When compared to the broader market, Morepen Laboratories has significantly underperformed. Over the past week, the stock declined by 6.77%, while the Sensex remained virtually flat with a marginal 0.06% gain. The one-month performance further ..."
      },
      {
        "title": "How has been the historical performance of Morepen Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-morepen-labs-3726354",
        "imagepath": "",
        "date": "2025-11-24 23:14:10",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Growth</strong></p>\n<p>Morepen Labs’ net sales have shown a consistent upward trend, increasing from ₹768.54 crores in March 2019 to ₹1,811.58 crores in March 2025. This represents a more than twofold increase over six years, reflecting the company’s expanding market presence and product portfolio. Despite a slight dip in sales in March 2022 compared to the previous year, the overall trajectory remains positive.</p>\n<p>Operating profit before depreciation and interest (PBDIT) excluding other income rose from ₹67.52 crores in 2019 to ₹174.07 crores in 2025, indicating improved operational efficiency. Including other income, operating profit increased to ₹192.43 crores in the latest fiscal year. Profit after tax (PAT) also followed a similar pattern, climbing from ₹28.84 cro..."
      },
      {
        "title": "Is Morepen Labs. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-morepen-labs-technically-bullish-or-bearish-3716888",
        "imagepath": "",
        "date": "2025-11-20 08:11:09",
        "description": "As of 19 November 2025, the technical trend for Morepen Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is bearish, and the daily moving averages confirm this bearish outlook. Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating some mixed signals. Overall, the Dow Theory supports a mildly bearish view on both weekly and monthly time frames. The stock has underperformed significantly against the Sensex over various periods, further reinforcing the bearish sentiment...."
      },
      {
        "title": "Morepen Laboratories Technical Momentum Shifts Amid Bearish Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/morepen-laboratories-technical-momentum-shifts-amid-bearish-signals-3716988",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MorepenLaborato_technicaldot_3716988.png",
        "date": "2025-11-20 08:04:29",
        "description": "Morepen Laboratories has experienced a notable shift in its technical momentum, with recent evaluation adjustments reflecting a predominantly bearish outlook across key indicators. This article analyses the current technical signals, price movements, and comparative returns to provide a comprehensive view of the stock’s market position within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Morepen Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-morepen-labs-fallingrising-3716355",
        "imagepath": "",
        "date": "2025-11-19 23:10:57",
        "description": "As of 19-Nov, Morepen Laboratories Ltd is experiencing a decline in its stock price, currently at 45.52, reflecting a decrease of 0.22 or 0.48%. The stock has underperformed its sector by 0.55% today and has been on a consecutive downward trend for the last five days, resulting in a total decline of 3.44% over that period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past year, the stock has generated a return of -40.00%, while its profits have fallen by 42.6%. The company has also reported negative results for the last three consecutive quarters, contributing to a lack of investor confidence, as indicated by the low participation from domestic mutual funds.\n\nIn the broader market context, the stock's recent performance contrasts sharply with the benchmark Sensex, which has gained 0.85% over the past week and 1.47% over the past month. Wh..."
      },
      {
        "title": "Is Morepen Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-morepen-labs-overvalued-or-undervalued-3709758",
        "imagepath": "",
        "date": "2025-11-18 08:20:47",
        "description": "As of 17 November 2025, Morepen Labs has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 33.58, an EV to EBITDA of 19.59, and a Price to Book Value of 2.12. \n\nIn comparison with its peers, Morepen Labs' PE ratio is lower than that of Sun Pharma, which stands at 36.69, but higher than Cipla's attractive valuation of 22.81. The PEG ratio for Morepen is notably low at 0.00, indicating potential growth concerns compared to peers like Divi's Lab, which has a PEG of 1.97. Additionally, Morepen Labs has underperformed the Sensex significantly over the past year, with a stock return of -38.87% compared to the Sensex's 9.50%...."
      },
      {
        "title": "Morepen Laboratories Faces Mixed Technical Trends Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/morepen-laboratories-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-volatility-3710483",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MorepenLaborato_technicaldot_3710483.png",
        "date": "2025-11-18 08:10:43",
        "description": "Morepen Laboratories, a small-cap pharmaceutical company, is currently facing market challenges, reflected in its recent stock price and year-to-date performance. Despite a positive three-year return, its five-year performance lags behind the Sensex. Technical indicators present a mixed outlook, suggesting potential volatility ahead."
      },
      {
        "title": "Morepen Laboratories Q2 FY26: Profit Surge Masks Underlying Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/morepen-laboratories-q2-fy26-profit-surge-masks-underlying-margin-pressures-3708071",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MorepenLaborato_quaterlyResult_3708071.png",
        "date": "2025-11-17 19:31:49",
        "description": "Morepen Laboratories Ltd. delivered a dramatic turnaround in Q2 FY26, posting consolidated net profit of ₹40.87 crores—a staggering 280.19% surge quarter-on-quarter from ₹10.75 crores in Q1 FY26. However, the pharmaceutical manufacturer's shares have declined 38.87% over the past year, trading at ₹46.23 as of November 17, 2025, reflecting persistent investor concerns about margin compression and operational headwinds despite the quarterly profit rebound."
      }
    ],
    "total": 348,
    "sid": "546345",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/morepen-laboratories-546345"
  },
  "announcements": [
    {
      "caption": "Report On Transfer Requests Of Physical Shares Re-Lodged Under The Special Window",
      "datetime": "28-Jan-2026",
      "details": "Please find attached the report for the period from 1 January 2026 to 6 January 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "08-Jan-2026",
      "details": "Please find attached disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Report On Transfer Requests Of Physical Shares Re-Lodged Under The Special Window",
      "datetime": "08-Jan-2026",
      "details": "Please find attached the report for the month of December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Morepen Laboratories Ltd has declared <strong>10%</strong> dividend, ex-date: 29 Aug 25",
          "dt": "2025-08-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Morepen Laboratories Faces Challenging Market Conditions Amid Mixed Financial and Technical Signals

2025-11-25 08:42:08

Morepen Laboratories, a player in the Pharmaceuticals & Biotechnology sector, is currently navigating a complex market environment marked by subdued financial results and cautious technical indicators. Recent shifts in evaluation metrics reflect a nuanced perspective on the company’s quality, valuation, financial trends, and technical outlook, underscoring the challenges it faces amid broader market dynamics.

Why is Morepen Labs. falling/rising?

2025-11-25 01:15:32

Recent Price Movement and Market Comparison On 24 November, Morepen Laboratories closed at ₹43.10, down by ₹0.91 or 2.07% from the previous session. This drop continues a downward trend, with the stock having fallen for eight consecutive days, resulting in an 8.57% loss over this period. The stock is trading close to its 52-week low, just 3.34% above the lowest price of ₹41.66 recorded during the past year. This proximity to the annual low signals persistent selling pressure and a lack of positive catalysts to reverse the trend. When compared to the broader market, Morepen Laboratories has significantly underperformed. Over the past week, the stock declined by 6.77%, while the Sensex remained virtually flat with a marginal 0.06% gain. The one-month performance further ...

How has been the historical performance of Morepen Labs.?

2025-11-24 23:14:10

Revenue and Profit Growth Morepen Labs’ net sales have shown a consistent upward trend, increasing from ₹768.54 crores in March 2019 to ₹1,811.58 crores in March 2025. This represents a more than twofold increase over six years, reflecting the company’s expanding market presence and product portfolio. Despite a slight dip in sales in March 2022 compared to the previous year, the overall trajectory remains positive. Operating profit before depreciation and interest (PBDIT) excluding other income rose from ₹67.52 crores in 2019 to ₹174.07 crores in 2025, indicating improved operational efficiency. Including other income, operating profit increased to ₹192.43 crores in the latest fiscal year. Profit after tax (PAT) also followed a similar pattern, climbing from ₹28.84 cro...

Is Morepen Labs. technically bullish or bearish?

2025-11-20 08:11:09

As of 19 November 2025, the technical trend for Morepen Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is bearish, and the daily moving averages confirm this bearish outlook. Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating some mixed signals. Overall, the Dow Theory supports a mildly bearish view on both weekly and monthly time frames. The stock has underperformed significantly against the Sensex over various periods, further reinforcing the bearish sentiment....

Morepen Laboratories Technical Momentum Shifts Amid Bearish Indicators

2025-11-20 08:04:29

Morepen Laboratories has experienced a notable shift in its technical momentum, with recent evaluation adjustments reflecting a predominantly bearish outlook across key indicators. This article analyses the current technical signals, price movements, and comparative returns to provide a comprehensive view of the stock’s market position within the Pharmaceuticals & Biotechnology sector.

Why is Morepen Labs. falling/rising?

2025-11-19 23:10:57

As of 19-Nov, Morepen Laboratories Ltd is experiencing a decline in its stock price, currently at 45.52, reflecting a decrease of 0.22 or 0.48%. The stock has underperformed its sector by 0.55% today and has been on a consecutive downward trend for the last five days, resulting in a total decline of 3.44% over that period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past year, the stock has generated a return of -40.00%, while its profits have fallen by 42.6%. The company has also reported negative results for the last three consecutive quarters, contributing to a lack of investor confidence, as indicated by the low participation from domestic mutual funds. In the broader market context, the stock's recent performance contrasts sharply with the benchmark Sensex, which has gained 0.85% over the past week and 1.47% over the past month. Wh...

Is Morepen Labs. overvalued or undervalued?

2025-11-18 08:20:47

As of 17 November 2025, Morepen Labs has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 33.58, an EV to EBITDA of 19.59, and a Price to Book Value of 2.12. In comparison with its peers, Morepen Labs' PE ratio is lower than that of Sun Pharma, which stands at 36.69, but higher than Cipla's attractive valuation of 22.81. The PEG ratio for Morepen is notably low at 0.00, indicating potential growth concerns compared to peers like Divi's Lab, which has a PEG of 1.97. Additionally, Morepen Labs has underperformed the Sensex significantly over the past year, with a stock return of -38.87% compared to the Sensex's 9.50%....

Morepen Laboratories Faces Mixed Technical Trends Amid Market Challenges

2025-11-18 08:10:43

Morepen Laboratories, a small-cap pharmaceutical company, is currently facing market challenges, reflected in its recent stock price and year-to-date performance. Despite a positive three-year return, its five-year performance lags behind the Sensex. Technical indicators present a mixed outlook, suggesting potential volatility ahead.

Morepen Laboratories Q2 FY26: Profit Surge Masks Underlying Margin Pressures

2025-11-17 19:31:49

Morepen Laboratories Ltd. delivered a dramatic turnaround in Q2 FY26, posting consolidated net profit of ₹40.87 crores—a staggering 280.19% surge quarter-on-quarter from ₹10.75 crores in Q1 FY26. However, the pharmaceutical manufacturer's shares have declined 38.87% over the past year, trading at ₹46.23 as of November 17, 2025, reflecting persistent investor concerns about margin compression and operational headwinds despite the quarterly profit rebound.

View All News